Back to Freepaper Session

Comparison of two combined cohesive and dispersive ophthalmic viscoelastic devices during cataract surgery

Session Details

Session Title: Surgical Outcomes

Session Date/Time: Monday 07/10/2013 | 08:00-09:30

Paper Time: 09:00

Venue: Auditorium (First Floor)

First Author: : M.Holzer GERMANY

Co Author(s): :    F. Auerbach   B. Thomas   R. Khoramnia   L. Kastlunger   T. Rabsilber   G.

Abstract Details

Purpose:

Aim of the multicenter study was to compare postoperative findings in terms of intraocular pressure (IOP) and endothelial cell count (ECC) using two different combined cohesive and dispersive ophthalmic viscoelastic devices (OVDs): Twinvisc (Carl Zeiss Meditec/Germany) vs. DuoVisc (Alcon Laboratories/USA).

Setting:

International Vision Correction Research Centre (IVCRC), Department of Ophthalmology, University of Heidelberg, Heidelberg, Germany

Methods:

54 cataract patients (age from 51 to 86 years) have been enrolled in this prospective, randomised, comparative, investigator-masked trial in Germany. Only one eye of each patient was part of the study and was randomised to receive either Twinvisc or DuoVisc during cataract surgery. IOP was measured before surgery as well as six hours, day 1, 7, 30 and 90 postoperatively. ECC measurements were done preoperatively and 90 days after surgery.

Results:

Median IOP six hours after surgery was 21.0 mmHg in the Twinvisc (n = 26) group and 20.8 mmHg in the DuoVisc (n=28) group. IOP peaks ?30 mmHg have been found in 2 of 26 eyes (7.7%) in the Twinvisc group compared to 5 of 28 eyes (17.9%) in the Duovisc group. A median ECC loss of -98.20 cells/mm2 (Twinvisc; n=21) and -107.40 cells/mm2 (DuoVisc; n= 21) was seen three months postoperatively which equals 3.79 % for Twinvisc and 4.40 % for DuoVisc. The differences between the groups were not statistically significant (p>0.05, Mann-Whitney-U-Test).

Conclusions:

Postoperative results indicate that Twinvisc showed less IOP peaks ?30 mmHg than DuoVisc and a comparable minor ECC loss of approximately 4% in median. The Twinvisc application was as secure as DuoVisc during cataract surgery.

Financial Interest:

... is employed by a for-monetary company with an interest in the subject of the presentation, ... travel has been funded, fully or partially, by a company producing, developing or supplying the product or procedure presented, ... research is funded, fully or partially, by a company producing, developing or supplying the product or procedure presented